From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Oteseconazole (VT-1161) is a potent and orally active anti-fungal agent. Oteseconazole potently binds to and inhibits Candida albicans cytochrome P45051 (CYP51) activity (Kd ≤39 nM), shows no obvious effect on human CYP51. Oteseconazole also can be used for the research of dermatophytes .
Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicansCYP51(CaCYP51) and truncated Homo sapiensCYP51(Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
Obtusifoliol is a specific CYP51 inhibitor, Obtusifoliol shows the affinity with Kd values of 1.2 μM and 1.4 μM for Trypanosoma brucei (TB) and human CYP51, respectively .
Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases .
PC945, a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus. PC945 is also a potent, tightly binding inhibitor of A. fumigatus sterol 14α-demethylase activity, CYP51A and CYP51B, with IC50s of 0.23 μM and 0.22 μM, respectively .
Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM) .
VT-1598 is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 shows anti-fungal activity against Candida auris . VT-1598 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Tebuconazole (Standard) is the analytical standard of Tebuconazole. This product is intended for research and analytical applications. Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicansCYP51(CaCYP51) and truncated Homo sapiensCYP51(Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
Tetraconazole is a selective irreversible inhibitor of 14-α-sterol demethylase (CYP51) with antifungal activity. Tetraconazole competitively binds to the enzyme to block fungal ergosterol synthesis, resulting in cell membrane damage. The EC50 of tetraconazole against wheat pathogens is 0.382-0.802 mg/L, and the EC50 against onion root tip meristem cell growth is 6.7 mg/L, and (R)-(+)-Tetraconazole is 1.49-1.98 times more active than (S)-(-)-Tetraconazole. Tetraconazole can also induce oxidative stress and chromosomal aberrations in plant cells .
Antifungal agent 136 (Compound M-15) is an irreversible fungal lanosterol 14α-demethylase (CYP51) inhibitor. Antifungal agent 136 exhibits potent antifungal activity against drug-resistant Candida albicans and downregulates IL-6 expression. Antifungal agent 136 is promising for research of fungal infection and inflammatory disease .
CYP51-IN-28 (compound B9) is a CYP51 inhibitor. CYP51-IN-28 is an efficient, broad-spectrum, and low toxicity antifungal molecule. CYP51-IN-28 can be used for research on fungal infections .
CYP51-IN-27 is a sterol 14α-demethylase CYP51 inhibitor with an IC50 of 0.3434 μg/mL. CYP51-IN-27 exhibits antifungal activity and inhibits the production of fungal ergosterol. CYP51-IN-27 can be used for the research of infection, such as rice sheath blight .
CYP51-IN-24 (Compound 22) is a Sterol 14α-Demethylase (CYP51) inhibitor. CYP51-IN-24 exhibits potent inhibitory activity against wild-type and drug-resistant fungi. CYP51-IN-24 inhibits ergosterol biosynthesis by binding to the fungal CYP51 enzyme. CYP51-IN-24 can be used in research and drug development against drug-resistant fungal infections .
CYP51-IN-25 is a orally active broad spectrum antifungal agent with the MIC80 of 0.00625-0.05 μg/mL. is a CYP51-IN-25 is a deuterated compound with antibiotic properties. CYP51-IN-25 can inhibit the fungal CYP51 enzyme, block ergosterol synthesis, and disrupt cell membrane integrity. CYP51-IN-25 can be used for research on fungal infections.
CYP51-IN-18 (compound 2l) is a potent CYP51 inhibitor with an IC50 of 0.219 μg/mL. CYP51-IN-18 shows significant fungicidal activity against B. cinerea with an EC50 of 0.369 μg/mL .
CYP51-IN-17 (compound 7a) is a potent CYP51 inhibitor with an IC50 of 0.377 μg/mL. CYP51-IN-17 shows significant fungicidal activity against B. cinerea with an EC50 of 0.326 μg/mL .
CYP51-IN-26 is a CYP51 inhibitor with an IC50 value of approximately 0.40 μM. CYP51-IN-26 eradicates C.
auris biofilms. CYP51-IN-26 demonstrates significantly improved intracellular uptake in an accumulation assay. CYP51-IN-26 protects against C. auris infection in both G. mellonella and D. melanogaster models. CYP51-IN-26 can be used for research on fungal infections .
CYP51-IN-30 is a CYP51 inhibitor and fungicidal agent. CYP51-IN-30 inhibits CYP51 activity. CYP51-IN-30 displays potent fungicidal activity with an EC50 value of 2.97 mg/L against S. sclerotiorum .
CYP51-IN-20 (compound 5b) is an inhibitor of CYP51 and has antifungal activity. CYP51-IN-20 has a significant inhibitory effect on Candida albicans ATCC 10231, downregulates ERG11 (Cyp51) gene expression, and significantly reduces the yeast-to-hyphae morphological transition. CYP51-IN-20 can synergize with Voriconazole (HY-76200) to occupy the entire CYP51 binding site and exert a synergistic inhibitory effect in the Glechoma moth model .
CYP51-IN-22, the non-deuterated analog of CYP51-IN-23-d3 (HY-174353S), is a potent and broad-spectrum CYP51inhibitor.CYP51-IN-22 inhibits Aspergillus fumigatum with a MIC80 of 1 μg/mL. CYP51-IN-22 can prevent fungal phase transformation and biofilm formation. CYP51-IN-22 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-22 can be used for the study of invasive fungal infections (IFIs) .
CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis .
Tebuconazole-d9 is the deuterium labeled Tebuconazole. Tebuconazole is an agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively.
CYP51/Hsp90-IN-1 (Compound MM4) is a dual CYP51/Hsp90 inhibitor. CYP51/Hsp90-IN-1 shows antifungal activity against Candida albicans and effectively inhibits important fungal virulence factors. CYP51/Hsp90-IN-1 is promising for research of invasive candidiasis .
CYP51-IN-23-d3 is a potent and broad-spectrum CYP51 inhibitor with a MIC80 of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d3 can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d3 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d3 can be used for the study of invasive fungal infections (IFIs) .
CYP51-IN-2 (compound 1n), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 1 μg/mL for Microsporum gypseum and Candida albicans .
CYP51-IN-2 (compound 1i), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 62.5 for Microsporum gypseum and Candida albicans .
CYP51-IN-2 (compound 1l), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans .
CYP51-IN-2 (compound 1d), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80 of 15.6 ng/mL for Microsporum gypseum and Candida albicans .
CYP51-IN-2 (compound 1m), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively .
CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target (CYP51/PD-L1) inhibitor, with IC50 values of 0.17 and 0.021 μM, respectively. CYP51/PD-L1-IN-4 exhibits excellent antifungal and antidrug-resistant fungal activity in vitro. CYP51/PD-L1-IN-4 can be used for fungal infections research .
VT-1598 tosylate is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 tosylate shows anti-fungal activity against C. auris . VT-1598 (tosylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CYP51-IN-2 (compound 1h), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 15.6 and 62.5 ng/mL for Microsporum gypseum and Candida albicans, respectively .
CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
CYP51-IN-10 is cytochrome P450 14a-demethylase(CYP51) inhibitor with antifungal activity. CYP51-IN-10 can be used for the research of fungal infection .
CYP51-IN-32 is an antifungal agent with an IC50 of 0.331 μM against CYP51 of Candida albicans. CYP51-IN-32 releases hydrogen sulfide (H2S) and inhibits hyphal formation and biofilm development of Candida albicans. CYP51-IN-32 can be formulated into PEG-based nanovesicles. CYP51-IN-32 is applicable to the research of Candida albicans infection .
Prothioconazole (Standard) is the analytical standard of Prothioconazole. This product is intended for research and analytical applications. Prothioconazole is a triazolinthione fungicide. Prothioconazole is a CYP51 inhibitor .
CYP51-IN-29 (Compound B3) is a CYP51 inhibitor and antifungal agent. CYP51-IN-29 effectively suppresses the yeast-to-hyphal transition. CYP51-IN-29 exhibits potent antifungal activity against Candida albicans .
CYP51-IN-21 (Compound A33) is a potent CYP51 inhibitor. CYP51-IN-21 shows excellent antifungal activities against pathogenic fungi and drug-resistant strains. CYP51-IN-21 inhibits the formation of fungal biofilm .
CYP51-IN-31 (compound T24) is a selective CYP51 inhibitor with potent and broad-spectrum antifungal activity, including efficacy against drug-resistant fungal strains. CYP51-IN-31 exhibits fungicidal activity against Candida parapsilosis, anti-biofilm activity, and the ability to inhibit fungal morphological transitions. CYP51-IN-31 can be used for infection research .
CYP51A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP51A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Antifungal agent 40 is an antifungal agent which extends into the narrow hydrophobic pocket II of C.alb.CYP51. Antifungal agent 40 has an inhibitory effect on lanosterol 14α-demethylase (CYP51). Antifungal agent 40 inhibits biofilm formation .
CYP51-IN-2 (compound 1g), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 250 ng/mL for Microsporum gypseum and Candida albicans, respectively .
CYP51-IN-2 (compound 1f), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows MIC80s of 62.5 and 15.6 ng/mL for Microsporum gypseum and Candida albicans, respectively .
CYP51-IN-2 (compound 1b), a Fluconazole (HY-B0101) analog, is a potent antifungal agent. CYP51-IN-2 shows 64 and 128 times higher activity than that of Fluconazole against Microsporum gypseum and Candida albicans, respectively .
Antifungal agent 68 (compound 10) is an antifungal agent against Candida and Cryptococcus gattii. Antifungal agent 68 inhibits fungal ergosterol biosynthesis, possibly by targeting lanosterol 14α-demethylase (CYP51). There is an interaction between the imidazole ring of antifungal agent 68 and the heme group of CYP51 .
Oteseconazole (Standard) is the analytical standard of Oteseconazole. This product is intended for research and analytical applications. Oteseconazole (VT-1161) is a potent and orally active anti-fungal agent. Oteseconazole potently binds to and inhibits Candida albicans cytochrome P45051 (CYP51) activity (Kd ≤39 nM), shows no obvious effect on human CYP51. Oteseconazole also can be used for the research of dermatophytes .
Tebuconazole-d6 is a deuterium labeled Tebuconazole (HY-B0852). Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicansCYP51(CaCYP51) and truncated Homo sapiensCYP51(Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
Antifungal agent 33 (compound 4e) is a potent antifungal agent. Antifungal agent 33 exhibits remarkable antifungal activity against C. albicans, with a MIC of 16 μg/mL. Antifungal agent 33 shows potent inhibitory activity against Lanosterol 14α-demethylase (CYP51), with an IC50 of 0.19 μg/mL .
SDH-IN-27 (Compound Q18) is a succinate dehydrogenase inhibitor (SDHI) (IC50: 9.7 mg/L). SDH-IN-27 induces mycelial morphology changes and lipid peroxidation, and exhibits antifungal activity against C. camelliae (EC50: 6.0 mg/L). SDH-IN-27 is an ergosterol biosynthesis inhibitor (EBI) that binds to the active site of CYP51, ultimately leading to cell death of pathogenic fungi .
Quilseconazole (Standard) is the analytical standard of Quilseconazole (HY-109040). This product is intended for research and analytical applications. Quilseconazole (VT-1129) is an orally active, highly selective fungal cytochrome P450 enzyme Cyp51 inhibitor that can cross the blood-brain barrier. Quilseconazole prevents the synthesis of ergosterol, an important component of the fungal cell membrane, by inhibiting Cyp51. Quilseconazole has minimal effects on human CYP enzymes. Quilseconazole has antifungal activity and can be used in the study of cryptococcal meningitis and other diseases .
Prothioconazole-d4 (JAU-6476-d4) is the deuterium labeled Prothioconazole (HY-116568). Prothioconazole is a triazolinthione fungicide. Prothioconazole is a CYP51 inhibitor .
Antifungal agent 30 (compound A18) is a potent antifungal agent. Antifungal agent 30 shows excellent antifungal activity against Candida albicans (CPCC400616) and Aspergillus fumigatus, with MIC of 0.03 and 0.5 μg/mL, respectively. Antifungal agent 30 also shows excellent antifungal activity against fluconazole-resistant strains. The potent antifungal activity of Antifungal agent 30 mainly causes by hydrogen and coordination bond interaction with the CYP51 .
Antifungal agent 42 is an antifungal agent. Antifungal agent 42 has an inhibitory effect on lanosterol 14α-demethylase (CYP51) of C.alb.. Antifungal agent 42 inhibits biofilm formation .
Antifungal agent 53 (A03) is a potent inhibitor of Candida albicans CYP51 with antifungal activity. Antifungal agent 53 prevents the formation of fungi biofilms. Antifungal agent 53 also exhibits good safety .
LP10 is a non-azole CYP51 inhibitor with activity against Trypanosoma cruzi infection. Treatment with LP10 blocks the 14α-demethylation step, leading to disruption of the parasite cell membrane and ultimately triggering the death of important clinically relevant amoeba stages .
Mefentrifluconazole (Standard) is the analytical standard of Mefentrifluconazole. This product is intended for research and analytical applications. Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM)[1].
(Rac)-Ketoconazole ((Rac)-R 41400) is an antifungal imidazole compound with oral activity. (Rac)-Ketoconazole interferes with ergosterol synthesis by inhibiting cytochrome P450-dependent 14α-sterol demethylase (CYP51), a key enzyme on the fungal cell membrane, leading to membrane dysfunction and ultimately inhibition of fungal growth and reproduction. (Rac)-Ketoconazole is indicated for studies of fungal infections .
Antifungal agent 137 (Compound 4S) is an antifungal agent. Antifungal agent 137 inhibits Phomopsis sp. (PS), with an EC50 of 0.15 μg/mL. Antifungal agent 137 inhibits lanosterol 14α-demethylase (CYP51), with an IC50 of 5.00 μg/mL. Antifungal agent 137 disrupts the morphology of PS mycelia, impairs cell membrane integrity, and induces an increase in intracellular ROS levels, triggering oxidative stress. Antifungal agent 137 can be used for the study of fungal infection .
Tebuconazole-d4 is the deuterium labeled Tebuconazole (HY-B0852). Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
Diorcinol D is a natural product with antifungal activity. Diorcinol D inhibits CYP51 expression, reduces Cdr1 expression, blocks efflux pump activity, and impedes ergosterol biosynthesis. It inhibits planktonic and biofilm growth of Candida albicans. Diorcinol D is applicable to research related to fungal infections .
Antifungal agent 25 is a potent broad-spectrum antifungal agent. Antifungal agent 25 shows antifungal effect against Candida albicans and fluconazole-resistant strain of Candida albicans. Antifungal agent 25 stable metabolic property in vivo .
Antifungal agent-162 (Compound 1c) is an Antifungal agent. Antifungal agent-162 exhibits potent in vitro antifungal activity against Candida albicans, Cryptococcus neoformans, Candida parapsilosis, Candida tropicalis, Candida krusei, and Microsporum gypseum (with MIC80 values ranging from 0.0156 to 0.25 μg/mL), while shows no activity against Aspergillus fumigatus .
Obtusifoliol is a specific CYP51 inhibitor, Obtusifoliol shows the affinity with Kd values of 1.2 μM and 1.4 μM for Trypanosoma brucei (TB) and human CYP51, respectively .
Diorcinol D is a natural product with antifungal activity. Diorcinol D inhibits CYP51 expression, reduces Cdr1 expression, blocks efflux pump activity, and impedes ergosterol biosynthesis. It inhibits planktonic and biofilm growth of Candida albicans. Diorcinol D is applicable to research related to fungal infections .
CYP51 Proteinas is a sterol 14α-demethylase that acts with an unknown physiological substrate and accepts electrons from the iron-sulfur ferredoxin Fdx. In vitro, it catalyzes the C14-demethylation of lanosterol, 24,25-dihydrolanosterol, and obtanyol, showing stereoselectivity in producing 8,14-diene. CYP51 Protein, Mycobacterium tuberculosis (sf9, His) is the recombinant CYP51 protein, expressed by Sf9 insect cells , with N-10*His labeled tag.
ERG11 Proteinas is a sterol 14α-demethylase, a key enzyme in the ergosterol biosynthetic pathway, particularly in the late pathway that occurs in the endoplasmic reticulum membrane. ERG11 catalyzes the three-step removal of the 14α-methyl group from lanosterol, releasing it as a formate, resulting in the conversion of the sterol into a key intermediate in ergosterol biosynthesis. ERG11 Protein, Saccharomyces cerevisiae (GST) is the recombinant ERG11 protein, expressed by E. coli , with N-GST labeled tag.
CYP51-IN-25 is a orally active broad spectrum antifungal agent with the MIC80 of 0.00625-0.05 μg/mL. is a CYP51-IN-25 is a deuterated compound with antibiotic properties. CYP51-IN-25 can inhibit the fungal CYP51 enzyme, block ergosterol synthesis, and disrupt cell membrane integrity. CYP51-IN-25 can be used for research on fungal infections.
Tebuconazole-d9 is the deuterium labeled Tebuconazole. Tebuconazole is an agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively.
CYP51-IN-23-d3 is a potent and broad-spectrum CYP51 inhibitor with a MIC80 of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d3 can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d3 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d3 can be used for the study of invasive fungal infections (IFIs) .
Tebuconazole-d6 is a deuterium labeled Tebuconazole (HY-B0852). Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicansCYP51(CaCYP51) and truncated Homo sapiensCYP51(Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
Prothioconazole-d4 (JAU-6476-d4) is the deuterium labeled Prothioconazole (HY-116568). Prothioconazole is a triazolinthione fungicide. Prothioconazole is a CYP51 inhibitor .
Tebuconazole-d4 is the deuterium labeled Tebuconazole (HY-B0852). Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
CYP51A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP51A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
